Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Elevance Health (ELV) Stock Forecast & Price Target (2026)

AI-generated analysis

📈 Elevance Health (ELV) trades at $419.17 with a consensus analyst price target of $457.00, indicating a 9% upside potential according to CleaRank Financial AI.

💰 Insiders have demonstrated conviction by purchasing $5.1 million in stock while selling only $3.7 million, signaling a net buy signal.

📉 Revenue estimates for the current and next quarters show a projected year-over-year decline of approximately 2.00%, lagging sector growth.

✅ The company recently exceeded EPS estimates by 19.97% in the quarter ending June 2026, demonstrating strong operational execution.

📊 Technical analysis shows the stock price is trading above its 50-day average of $397.60 with an RSI of 62 in neutral territory.

🔮 Long-term Monte Carlo simulations project a base case price near $615 by 2030, representing a 1.5x return from current levels over four years.

📉 A ten-year backtest indicates that an investment in ELV would have grown to approximately $34,119 compared to $35,344 for the S&P 500 benchmark.

Bullish Signals
  • Insiders purchased $5.1 million worth of stock against $3.7 million in sales, signaling a net buy signal and potential institutional conviction.
  • The company recently exceeded EPS estimates by 19.97% in the quarter to June 2026, indicating strong operational execution.
  • A majority of analysts maintain Buy or Overweight ratings with a median price target of $457.00, reflecting general Wall Street optimism.
  • Technical indicators show the stock trading above its 50-day average at $397.60 with an RSI of 62 in neutral territory.
Risk Factors
  • Current and next quarter revenue estimates project a year-over-year decline of approximately 2.00%, lagging behind the sector's positive growth.
  • Historical monthly performance trends show that a $10,000 investment in ELV would be worth about $34,119 today compared to $35,344 for the S&P 500 benchmark.
Full Analysis
Elevance Health (ELV) is currently trading at $419.17 as of September 15, 2026, with technical indicators showing the stock above its 50-day average and an RSI in neutral territory. Financial analysts maintain a consensus price target of $457.00, representing a fair value approximately 9% higher than the current market price, supported by a majority of Buy or Overweight ratings from Wall Street. Operational performance highlights include a recent history of exceeding earnings per share (EPS) estimates, with the most recent quarter to June 2026 showing a beat of 19.97%. However, revenue estimates for the current and next quarters project a year-over-year decline of approximately 2.00%, which lags behind the broader sector's positive growth trajectory. Insider trading activity presents a mixed but slightly bullish signal, with insiders purchasing $5.1 million worth of stock compared to $3.7 million in sales over the reporting period. Long-term simulations by CleaRank project significant potential growth, estimating a base case value near $615 by 2030 and a bull case reaching $92,933 for a $10,000 investment by 2036, though these are statistical projections rather than guarantees. Despite the positive analyst sentiment and insider buying, the company faces headwinds from projected revenue contraction. The stock's performance relative to the S&P 500 has historically been slightly underperforming over a ten-year backtest period, suggesting investors should weigh the operational execution against sector-wide growth trends.